GURUFOCUS.COM » STOCK LIST » USA » NAS » HilleVax Inc (NAS:HLVX) » Definitions » EV-to-EBIT
Switch to:

HilleVax EV-to-EBIT

: (As of Today)
View and export this data going back to 2022. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, HilleVax's Enterprise Value is $504.51 Mil. HilleVax does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2021. Therefore, GuruFocus does not calculate HilleVax's EV-to-EBIT at this moment.

The historical rank and industry rank for HilleVax's EV-to-EBIT or its related term are showing as below:

HLVX' s EV-to-EBIT Range Over the Past 10 Years
Min: -5.69   Med: 0   Max: 0
Current: -4.92

HLVX's EV-to-EBIT is ranked worse than
100% of 486 companies
in the Biotechnology industry
Industry Median: 7.36 vs HLVX: -4.92

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. HilleVax's Enterprise Value for the quarter that ended in Dec. 2021 was $0.00 Mil. HilleVax does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2021. Therefore, GuruFocus does not calculate HilleVax's Earnings Yield (Joel Greenblatt) % at this moment.


HilleVax EV-to-EBIT Historical Data

The historical data trend for HilleVax's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HilleVax Annual Data
Trend Dec20 Dec21
EV-to-EBIT
- -

HilleVax Semi-Annual Data
Dec20 Dec21
EV-to-EBIT - -

Competitive Comparison

For the Biotechnology subindustry, HilleVax's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

HilleVax EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, HilleVax's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where HilleVax's EV-to-EBIT falls into.



HilleVax EV-to-EBIT Calculation

HilleVax's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=504.509/
=


HilleVax  (NAS:HLVX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

HilleVax's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2021 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2021 ) =EBIT / Enterprise Value (Q: Dec. 2021 )
=/0
= %


HilleVax EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of HilleVax's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


HilleVax Business Description

HilleVax logo
Traded in Other Exchanges
N/A
Address
Website
Executives
Fhmls X, L.l.c. 10 percent owner 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101
Dubin Gary director C/O HILLEVAX, INC. 75 STATE STREET, SUITE 100 - #9995 BOSTON MA 02109
Borkowski Astrid officer: Chief Medical Officer C/O HILLEVAX, INC. 75 STATE STREET, SUITE 100 - #9995 BOSTON MA 02109
Sepulveda Jaime director C/O HILLEVAX INC. 75 STATE STREET 100 - #9995 BOSTON MA 02109
Takeda Vaccines, Inc. 10 percent owner 75 SIDNEY STREET CAMBRIDGE MA 02139
Chu Shelley director ONE WINTHROP SQUARE SUITE 400 BOSTON MA 02110
Silbermann Susan Michele director C/O LIANBIO 103 CARNEGIE CENTER DRIVE, SUITE 215 PRINCETON NJ 08540
Fhmls X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101
Frazier Life Sciences X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101
Gerberding Julie L. director 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033
Kohli Aditya director, officer: Chief Operating Officer C/O PHATHOM PHARMACEUTICALS, INC. 2150 E. LAKE COOK ROAD, SUITE 800 BUFFALO GROVE IL 60089
Socks David A officer: CFO & Chief Business Officer C/O CADENCE PHARMACEUTICALS, INC. 12481 HIGH BLUFF DRIVE, SUITE 200 SAN DIEGO CA 92130
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO M0 103-8668
Hershberg Robert director, officer: President and CEO 3005 FIRST AVENUE SEATTLE WA 98121
Topper James N 10 percent owner 550 HAMILTON AVENUE, SUITE 100 PALO ALTO CA 94301
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)